Clinical trialNCT00796978CompletedPhase 2Interventional

Trastuzumab in Treating Older Women With Early-Stage Breast Cancer

SponsorCynthia Owusu, MDEnrollment56Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying the side effects of trastuzumab and to see how well it works in treating older women with early-stage breast cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Cynthia Owusu, MD, MSc
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Miami, Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Wake Forrest
Winston-Salem, North Carolina, United States
Lake/university Seidman Cancer Center
Cleveland, Ohio, United States
Southwest General Health Center
Cleveland, Ohio, United States
Uhhs Chagrin Highlands Medical Center
Cleveland, Ohio, United States
Uhhs Westlake Medical Center
Cleveland, Ohio, United States
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
University Suburban Health Center
Cleveland, Ohio, United States
Uh-Monarch
Mayfield Heights, Ohio, United States
Sharon Health Center
Wadsworth, Ohio, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Trastuzumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 5 Feb 2009
Primary completion: 6 Jan 2016
Completion: 26 Feb 2020
Last update posted: 1 May 2024
Registered enrollment: 56
Registry id: NCT00796978

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.